[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenoma-colon\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenoma-colon":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,87,113,134,156,186,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604180","clinical-evaluation-of-a-new-platform-for-bi-manual-endoscopic-resection-in-the-rectum-and-sigma-endotem-100604180",false,"NCT07146165","Clinical Evaluation of a New Platform for Bi-manual Endoscopic Resection in the Rectum and Sigma (EndoTEM)","EndoTEM","Inclusion Criteria:\n\n* Availability of written informed consent from the patient\n* Age \\> 18 years\n* Adenoma or early carcinoma \\> 2 cm in the rectum or distal sigmoid colon with indication for endoscopic en bloc resection using endoscopic submucosal dissection\n\nExclusion Criteria:\n\n* Informed consent not possible (e.g., language barrier)\n* Stenoses or fistulas in the anal region\n* Distance to the anocutaneous line ≤ 2 cm\n* Distance to the anocutaneous line \\> 20 cm\n* Individual medical assessment required for patients taking anticoagulant medication, in accordance with current ESGE guidelines\n* Pregnancy or breastfeeding\n* Vulnerable individuals","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine whether the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon is feasible and safe.\n\nThe main questions it aims to answer are:\n\n* Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon feasible (i.e., does it enable complete resection of the polyp)?\n* Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon safe?\n\nParticipants will:\n\n* be treated with the EndoTEM system during the endoscopic submucosal dissection of polyps in the distal colon.\n* answere questionnaires on fecal continence and quality of life before and after the intervention.\n* be treated following standard clinical procedures before, during and after the endoscopic removal.",[26,27],"Adenoma Colon Polyp","Adenoma Colon",[29,30,31,32,33],"endoscopic submucosal dissection","endoscopic en bloc resection","EndoTEM system","endoscopic portsystem","ESD","RECRUITING","2026-03-30",{"date":37,"type":38},"2026-03-31","ACTUAL",{"date":40,"type":38},"2025-10-02",{"date":42,"type":20},"2028-08",{"name":44,"class":45},"Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100627590","liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection-100627590","NCT07450612","Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","BEACON","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inflammatory bowel disease",true,{"count":56,"type":20},1200,"OBSERVATIONAL","This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.",[60,27,26,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Colorectal Cancer","Colon Adenoma","Colo-rectal Cancer","Colon Disease","Colon Neoplasm","Lynch Syndrome","Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","LYN Gene Mutation","Mismatch Repair Deficiency","Mismatch Repair Gene Mutation","MLH1 Gene Mutation","MSH2 Gene Mutation","MSH6 Gene Mutation","PMS2 Gene Mutation","EPCAM Gene Mutation","2026-02-27",{"date":79,"type":38},"2026-03-04",{"date":81,"type":38},"2024-01-01",{"date":83,"type":20},"2031-08-15",{"name":85,"class":45},"San Raffaele University",4,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100604741","identification-of-new-non-invasive-predictive-and-diagnostic-biomarkers-for-colorectal-cancer-100604741","NCT07153458","Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer","Inclusion Criteria:\n\n* AIM 1: Patients undergoing surgery at the U.O.C. of Surgery, with a diagnosis of CRC.\n* AIM 2: Subjects without colon disease.\n* AIM 3: Subjects with adenoma and high-grade dysplasia.\n\nExclusion Criteria:\n\n* Subject with any other pathology not included in the inclusion criteria.",{"count":94,"type":20},60,"The study in question is an observational study that aims to identify new non-invasive biomarkers present in the serum of patients with CRC and, subsequently, to create a score capable of predicting the development of CRC.\n\nIt is an observational study with 3 enrollment arms:\n\nArm 1: Patients undergoing surgery at the U.O.C. of Surgery, with a CRC diagnosis;\n\nArm 2: Subjects with a negative result from the endoscopic examination;\n\nArm 3: Subjects in whom the presence of an adenoma with high-grade dysplasia is found, a condition considered pre-cancerous.",[97,27],"CRC (Colorectal Cancer)",[99,100,101,102],"crc (colorectal cancer)","Adenoma colon","Biomarkers","neoplasm","2025-12-12",{"date":105,"type":38},"2025-12-19",{"date":107,"type":38},"2025-12-01",{"date":109,"type":20},"2027-12-01",{"name":111,"class":45},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":54,"sex":16,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":112},"100595492","an-exploratory-study-on-gene-methylation-detection-of-colorectal-cancer-100595492","NCT07033156","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer（CRC）","Inclusion Criteria:\n\n1. Sample Source: Hospital physical examination, outpatient, and inpatient patients;\n2. Patient Information: Patient information (such as age, hospital ID number, gender, clinical diagnosis, colonoscopy and pathology results) is traceable;\n3. Age Requirement: ≥ 40 years old;\n4. Sampling Time Requirement: Stool and plasma samples must be collected within 3 months prior to colonoscopy (stool samples are preferred).\n\nExclusion Criteria:\n\n1. Unclear Sample Collection Information: Samples with unclear collection time, or stool samples not collected within 3 months prior to colonoscopy, or samples with incomplete clinical information that cannot be traced;\n2. Non-compliance with Sample Requirements: Samples that do not meet the collection and storage requirements;\n3. History of Disease: Subjects with a history or treatment of colorectal cancer (CRC) or advanced precancerous lesions;\n4. Insufficient Sample Volume: Samples with insufficient volume that cannot meet the requirements of the assessment system testing;\n5. Hereditary Diseases: Subjects with a diagnosis or family history of the following diseases:Familial adenomatous polyposis (FAP), including attenuated FAP and Gardner syndrome;Hereditary nonpolyposis colorectal cancer syndrome (HNPCC or Lynch syndrome);Other hereditary cancer syndromes, including but not limited to Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Turcot syndrome (or Crail syndrome), Cowden syndrome, juvenile polyposis, neurofibromatosis, or familial proliferative polyposis (FAP);\n6. Inflammatory Bowel Disease (IBD): Subjects with a diagnosis or personal history of IBD, including chronic ulcerative colitis and\u002For Crohn's disease;\n7. Cronkhite-Canada Syndrome: Subjects with a diagnosis of Cronkhite-Canada syndrome.","40 Years",{"count":122,"type":20},450,"The goal of this exploration study is to evaluate the performance of a colorectal cancer (CRC) early screening model based on the DNA methylation technology platform. The study focuses on individuals over the age of 40 and aims to identify and verify methylation biomarkers for colorectal cancer using stool samples . The main question it aims to answer is:\n\nCan a DNA methylation-based model effectively detect colorectal cancer and adenoma in individuals over 40 using non-invasive stool samples?\n\nParticipants will provide stool samples for methylation analysis. The study results will be used solely for internal product performance evaluation and optimization by the sponsor and will not be used for product registration or influence any clinical diagnosis.",[97,27],"2025-06-25",{"date":127,"type":38},"2025-06-29",{"date":129,"type":38},"2024-12-24",{"date":131,"type":20},"2025-10-20",{"name":133,"class":45},"Zhejiang Provincial People's Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":112},"100511106","white-light-vs-narrow-band-imagingin-the-diagnosis-of-right-sided-colonic-polyps-in-asymptomatic-subjects-undergoing-screening-colonoscopy-100511106","NCT05935124","White Light vs Narrow Band Imagingin the Diagnosis of Right Sided Colonic Polyps in Asymptomatic Subjects Undergoing Screening Colonoscopy","A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Right Sided Colonic Polyps in Asymptomatic Subjects Undergoing Screening Colonoscopy","WLEvsB-NBI","Inclusion Criteria:\n\n* Asymptomatic subjects undergoing screening colonoscopy\n* age \\> 50.\n* average risk subjects defined as those without a personal history of inflammatory bowel disease, colon adenoma or cancer or family history of FAP or Familial non-polyposis syndrome or first degree relatives having diagnosed to have colo-rectal carcinoma, no colonoscopy in past 5 years and, ability to provide a written consent to trial participation\n\nExclusion Criteria:\n\n* unable to consent",{"count":143,"type":20},600,[23],"A randomized controlled crossover study to determine if narrow band imaging or white light endoscopy is superior in detecting right colonic polyps in average risk subjects undergoing screening colonoscopy",[27],"2025-03-25",{"date":149,"type":38},"2025-03-30",{"date":151,"type":38},"2015-08-01",{"date":153,"type":20},"2025-11",{"name":155,"class":45},"Western Sydney Local Health District",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100576924","surveillance-intervals-after-piecemeal-resection-of-non-pedunculated-colorectal-lesions-20mm-100576924","NCT06791616","Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm","Evaluation of Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm: SCARFACE Clinical Trial","Inclusion Criteria:\n\n* Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.\n* Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Resection performed using a cold snare technique due to the high risk of recurrence.\n* Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.\n* Absence of information regarding the grade of dysplasia of the index lesion.\n* Personal history of colorectal cancer.\n* Incomplete endoscopic resection of the index lesion or any other polyps present in the patient.\n* When the endoscopist performing the index colonoscopy expresses doubts about whether the resection was complete.\n* Index lesion with prior attempted resection.\n* Hereditary cancer syndromes (e.g., adenomatous or serrated polyposis syndromes, Lynch syndrome, etc.).\n* Inflammatory bowel disease.\n* Severe comorbidities with reduced life expectancy.\n* Pregnancy.\n* Ongoing cytotoxic treatment or radiotherapy for a malignant disease.","85 Years",{"count":165,"type":20},746,[23],"Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.\n\nThe multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.\n\nPatients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.",[169,27,170,171,172,173,174,175],"Colorectal Neoplasms","Colonic Polyps","Serrated Adenoma","Endoscopic Mucosal Resection","Non-pedunculated Lesions","Thermal Ablation","Recurrence","NOT_YET_RECRUITING","2025-01-19",{"date":179,"type":38},"2025-01-24",{"date":181,"type":20},"2025-03-01",{"date":183,"type":20},"2030-05-31",{"name":185,"class":45},"Asociación Española de Gastroenterología",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":195,"conditions":196,"keywords":201,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":112},"100444184","early-diagnosis-real-time-healthcare-system-for-cancer-trial-100444184","NCT05064124","Early DiAgnosis Real-Time Healthcare System for CANcer Trial","EARTHSCAN","Inclusion Criteria:\n\n* Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy with an endoscopist participating in the study phase of the trial.\n* Male and female participants aged 18 years or older at the time of informed consent.\n* Participants able to comprehend, sign and date the written informed consent document to participate in the study.\n\nExclusion Criteria:\n\n* Emergency and\u002For inpatient colonoscopies\n* Participants with inflammatory bowel disease (IBD)\n* Participants with current Colorectal Cancer (CRC)\n* Participants with a contraindication for biopsy or polypectomy. These include:\n\n  * Participants who have not withheld medications pre-disposing to bleeding at time of colonoscopy as per local site \u002Fnational guidelines.\n  * Participants with a history of haemostasis disorders (haemostasis disorders will include but will not be limited to: participants with haemophilia or other congenitally acquired clotting factor deficiencies, participants with cirrhosis with coagulopathy, participants known to have thrombocytopenia (\\\u003C80,000 platelet\u002Ful) and individuals with Von Willebrand's disease or other known platelet malfunction disorders)\n* Participant is enrolled in another research study with an investigational medicinal product (IMP) or non-IMP that pre-disposes them to bleeding",{"count":194,"type":20},420,"The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Participants will either have a colonoscopy with the assistance of the CADDIE device characterisation AI system (\"intervention group\") or have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system (\"control group\"). The randomisation method of this trial will allocate enrolled participants to the \"intervention\" group and to the \"control\" group by a technique similar to flipping a coin.",[197,27,198,199,200],"Polyps","Colorectal Polyp","Colon Polyp","Polyps of Colon",[202,203,204],"Artificial intelligence","Endoscopy","ADR","2024-12-10",{"date":207,"type":38},"2024-12-16",{"date":209,"type":38},"2024-07-18",{"date":211,"type":20},"2025-05",{"name":213,"class":45},"University College, London",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":112},"100420568","the-effect-of-clip-traction-on-esd-resection-time-100420568","NCT04756453","The Effect of Clip-traction on ESD Resection Time.","The Effect of Clip-traction on ESD Resection Time. A Randomized Controlled Trial","Inclusion Criteria:\n\n* a lesion in the colon or rectum suitable for removal by the ESD technique\n\nExclusion Criteria:\n\n* dementia\n* inability to understand the written study information","95 Years",{"count":223,"type":20},280,[23],"Patients scheduled for an endoscopic submucosal dissection(ESD) in the colorectum will be randomized to the use of a traction device(consisting of an endoscopic clip with a loop of dental floss secured in the lesion to be removed, another clip will anchor the loop to adjacent bowel wall) or a standard ESD.",[27],"2024-10-12",{"date":229,"type":38},"2024-10-15",{"date":231,"type":38},"2021-02-15",{"date":233,"type":20},"2025-11-15",{"name":235,"class":45},"Karolinska Institutet"]